Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(44.4%)
Phase 3
3(33.3%)
Phase 1
2(22.2%)
9Total
Phase 2(4)
Phase 3(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06277245Phase 3Completed

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

Role: lead

NCT07071610Phase 2Completed

A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis

Role: lead

NCT06276998Phase 3Active Not Recruiting

A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)

Role: lead

NCT07237568Phase 3Recruiting

A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis

Role: lead

NCT06553287Phase 1Completed

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

Role: lead

NCT06085534Phase 2Completed

A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis

Role: lead

NCT06085521Phase 2Completed

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Role: lead

NCT06099535Phase 2Completed

A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis

Role: lead

NCT04896112Phase 1Withdrawn

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Role: lead

All 9 trials loaded